EMPYREAN(SZ:301269) Xin Lang Cai Jing·2025-08-16 02:25Core Insights - The company BGI Genomics (301269.SZ) reported a total operating revenue of 502 million yuan for the first half of 2025, an increase of 57.75 million yuan compared to the same period last year, marking a 13.01% year-on-year growth [1] - The net profit attributable to shareholders was 3.07 million yuan, a decrease of 34.80 million yuan from the same period last year, representing a 91.90% decline [1] - The net cash inflow from operating activities was 243 million yuan, an increase of 249 million yuan compared to the same period last year [1] Financial Ratios - The latest debt-to-asset ratio is 8.11%, which is an increase of 0.39 percentage points from the previous quarter but a decrease of 1.67 percentage points from the same period last year [3] - The latest gross profit margin is 89.12%, down 2.29 percentage points from the previous quarter and down 2.27 percentage points from the same period last year [3] - The latest return on equity (ROE) is 0.06%, a decrease of 0.72 percentage points from the same period last year [3] Earnings and Turnover - The diluted earnings per share are 0.01 yuan, a decrease of 0.06 yuan compared to the same period last year, reflecting a 91.83% decline [4] - The latest total asset turnover ratio is 0.09 times, an increase of 0.01 times from the same period last year, marking a 10.93% year-on-year growth [4] - The latest inventory turnover ratio is 0.91 times, an increase of 0.13 times from the same period last year, representing a 16.44% year-on-year increase [4] Shareholder Structure - The number of shareholders is 37,800, with the top ten shareholders holding 436 million shares, accounting for 80.34% of the total share capital [4] - The largest shareholder is China Electronics Corporation, holding 21.22% of the shares [4] - Other significant shareholders include Beijing Jiuchuang Huixin Asset Management Partnership (17.63%) and China Electronics Investment Holdings (12.84%) [4]